aTyr Pharma, Inc.(US:ATYR) Prnewswireยท2025-10-24 17:37Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses due to misleading statements about the efficacy of its drug, Efzofitimod [1][2][4]. Group 1: Class Action Details - The new class action, King v. aTyr Pharma Inc., covers investors who acquired aTyr securities between November 7, 2024, and September 12, 2025, significantly extending the previous class period that began in January 2025 [2][4]. - The lawsuit alleges that aTyr and its executives made false statements regarding the drug's efficacy, leading to inflated stock prices [4][7]. Group 2: Drug Study and Allegations - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which evaluated Efzofitimod in patients with pulmonary sarcoidosis, aimed at reducing steroid dependency [5][6]. - Throughout the class period, aTyr executives reportedly expressed confidence in the study's design while allegedly concealing adverse facts about the drug's efficacy [6][7]. Group 3: Market Reaction - The truth about the drug's failure to meet its primary endpoint was revealed on September 15, 2025, leading to a drastic decline in aTyr's stock price from $6.03 to $1.02, a drop of 83.2% in one day [8][9]. - Following the announcement, aTyr indicated plans to engage with the FDA to determine a path forward after the setback [9]. Group 4: Investigation and Legal Actions - Hagens Berman, a prominent shareholders rights firm, is investigating whether aTyr misled investors about the drug's data and trial design, emphasizing its potential multi-billion-dollar market opportunity [10]. - The firm is urging affected investors to submit their losses and is seeking information from individuals who may assist in the investigation [3][11].